Five things for pharma marketers to know: Tuesday, August 22, 2017

1. Novartis launched a research study into multiple sclerosis using Apple's ResearchKit. The study, which will take place solely in a mobile app, will aim to understand the daily challenges faced by patients with the disease. Novartis markets MS drug Gilenya. (PMLIVE)

2. The FDA is weighing whether to limit the risk information in DTC TV and radio drug ads. The agency announced it was accepting comments on a “limited risks plus disclosure” strategy. The news comes after an FDA study found that limited risk disclosures could improve viewers' ability to retain and understand risk information. (RAPS)

3. Johnson & Johnson said it does not support or condone the use of its medicines for lethal injections for capital punishment, responding to plans by Florida authorities to use its etomidate in executions. (WSJ)

4. A jury awarded a woman from California $417 million saying she developed ovarian cancer from using Johnson & Johnson's baby powder for decades. (CNN)

5. In other Novartis news, the Swiss drugmaker is launching clinical trials for KAF156, an experimental medicine for drug-resistant malaria. Testing will begin in nine countries in Africa and Asia. (Reuters)